✓ No active regulatory warningsFDA MedWatch, EMA EudraVigilance, WHO VigiBase, WADA Prohibited List · 2026-05-29
Updated: 2026-05-29 · v2.0 · Prof. G. Pkhakadze, MD, MPH, PhDCiteEditorial
📰Read the full Omega-3 EPA evidence review on GMJ News →Complete clinical article, references and updates on news.gmj.ge. This page is the structured safety summary.
1
Safe
Omega-3 EPA
Eicosapentaenoic acid
Generally SafeStrongFatty Acids
RDA
250–500 mg EPA+DHA
Target
TG reduction 20–45%
Upper limit
FDA: up to 3 g
Products
1
Dosage by population group — reference
🔗 Best with: Omega-3 DHA, Vitamin E, Coenzyme Q10✅ IFOS (International Fish Oil Standards), USP Verified, NSF Contents Certified
⚠ REDUCE-IT: 25% CV event reduction with pure EPA (NNT=21) [2]
⚠ STRENGTH (EPA+DHA) was negative — pure EPA may be superior [2]
⚠ Depression: EPA-predominant (≥60%) formulations only [1]
⚠ Antiplatelet at >3 g/day [1]
🥗 Food first — build your daily 250–500 mg EPA+DHA
Check the foods you regularly eat — the bar fills toward your daily target.
0 mg EPA
Check your regular foods above
🔬 Lab interpreter
Recommended test
Triglycerides, lipid panel
Reference range / target
TG reduction 20–45%
When to test
8–12 weeks [2].
REDUCE-IT criteria: TG 150–499 on statin [2].
Full lab monitoring ↓
⚕ For professionals — confirm ranges against your local laboratory.
Clinical verdict
EPA is the anti-inflammatory omega-3. REDUCE-IT: pure EPA 4 g/day (Vascepa) reduced CV events 25% — the most important supplement-to-drug trial ever. EPA-predominant for depression (meta-analyses favor ≥60% EPA). STRENGTH trial (EPA+DHA) was negative — EPA alone may be the key. See Fish Oil entry for comprehensive data [1] [2].
1 Am I deficient?
Not applicable0%

What happens as status declines

Not applicable
Not an essential nutrient [1].

Risk factors

• Not applicable — not an essential nutrient [1]
🧬 How Omega-3 EPA works ▼
Eicosapentaenoic acid is a long-chain omega-3 that competes with arachidonic acid for cyclooxygenase and lipoxygenase, shifting eicosanoid output toward less inflammatory series-3 prostaglandins and series-5 leukotrienes, and serving as a precursor to pro-resolving resolvins. It lowers triglycerides and carries the strongest omega-3 evidence base for cardiovascular and mood endpoints.
2 How much do I need?
👤 Adults: Specific dosage data under clinical review
👴 Elderly: Specific dosage data under clinical review
🤰 Pregnancy: See guidance
DHA prioritized for brain. EPA + DHA both recommended [1].
👦 Pediatric: See guidance
See Fish Oil entry [1].
🏃 Athletes: Standard dose
⚖️ Obesity: Standard dose
Fat-soluble compounds may require dose adjustment in obesity.
🩺 Renal: Consult specialist
Dose adjustment may be needed in renal impairment.
🌱 Vegan: Standard dose

How to take

🍽 Timing: With fat-containing meal [1].
💊 With food: With fat [1].
🚫 Avoid: See Fish Oil entry [1].
3 Which form?
FormBioavailabilityVeganCost
['Vascepa/icosapent ethyl (Rx)', 'preferred', 'Pure EPA ethyl ester. 4 g/day. FDA-approved CV indication [2].']StandardCheck label
['EPA-concentrated fish oil', 'common', 'OTC. Various EPA concentrations [1].']StandardCheck label
['Algae EPA', '', 'Newer algae strains produce EPA (not just DHA) [1].']StandardCheck label
4 Common questions
Why did REDUCE-IT use pure EPA, not fish oil? ▼
REDUCE-IT specifically tested pure EPA (no DHA). The STRENGTH trial (EPA+DHA) was negative for CV outcomes. This suggests EPA's anti-inflammatory mechanism is specific and DHA may have diluted the benefit in mixed formulations. The debate continues [2].
EPA vs DHA for depression? ▼
Meta-analyses consistently favor EPA-predominant formulations (≥60% EPA). DHA-predominant formulations are not significantly better than placebo for depression. The mechanism may involve EPA's effects on neuroinflammation [1].
5 Clinical evidence

Strong

REDUCE-IT (n=8,179): pure EPA 4 g/day reduced MACE by 25% in statin-treated patients with TG 150–499. NNT=21 [2]. EPA competes with arachidonic acid for COX/LOX: established eicosanoid pharmacology [1]. HIGH

Moderate

Depression: meta-analyses favor EPA-predominant formulations over DHA-predominant or placebo [1]. Triglycerides: EPA 2–4 g/day reduces TG 20–45% [1]. Anti-inflammatory: reduced CRP and inflammatory markers [1]. MODERATE

Insufficient

Cancer prevention [1]. Cognitive enhancement (EPA — DHA is the brain fatty acid) [1]. See Fish Oil entry for comprehensive evidence. LOW
6 Safety, toxicity & adverse events

Absolute contraindications

✕ Fish/seafood allergy (fish-derived products)

Relative

⚠ High doses with anticoagulants/antiplatelets — bleeding risk
⚠ Discontinue high doses before surgery
⚠ Atrial fibrillation — a dose-related signal at high intake is under study

🚩 Red flags

● AFib history — REDUCE-IT showed increased AFib with high-dose EPA [2]
● Anticoagulant + high-dose EPA — bleeding [1]
7 Interactions

Drug interactions

Anticoagulants Moderate
Mechanism: EPA antiplatelet effects at >3 g/day. [1]
Effect: Bleeding risk. [1]
Action: Monitor [1].

Supplement synergies

Statin (for REDUCE-IT benefit) · Per cardiology
REDUCE-IT: Vascepa added to statin therapy [2].
8 Laboratory monitoring
Triglycerides, lipid panel Primary
Target: TG reduction 20–45% · 8–12 weeks [2].
Omega-3 index Primary
Target: >8% · 3 months [1].
9 Regulatory
United States (FDA): Vascepa (icosapent ethyl): FDA-approved to reduce CV risk in statin-treated patients with elevated TG (2019). Landmark supplement-to-drug transition [2].
10 US supplement products
1
on-market products containing Omega-3 EPA (NIH DSLD)

Brands carrying Omega-3 EPA (1)

Click a brand to see its Omega-3 EPA products.
Or browse all 1 products in one list →
11 Frequently paired with
Ashwagandha 1 shared
Omega-3 EPA vs Omega-3 DHAOmega-3 EPA vs Vitamin E
12 References (2)
[1]National Institutes of Health, ODS. Omega-3. Updated 2024. ods.od.nih.gov REVIEW Accessed: 2026-05-29
[2]Bhatt DL, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia (REDUCE-IT). N Engl J Med. 2019;380(1):11-22. doi:10.1056/NEJMoa1812792 REVIEW Accessed: 2026-05-29
13 Cite this page
Vancouver: Pkhakadze G. Omega-3 EPA — safety profile [Internet]. Tbilisi: PHIG; 2026 [cited 2026 Aug 24]. Available from: https://supplement.ge/ingredients/epa/
APA 7th: Pkhakadze, G. (2026). Omega-3 EPA — Safety profile. Public Health Institute of Georgia. https://supplement.ge/ingredients/epa/
📋 Editorial information
Author: Prof. G. Pkhakadze, MD, MPH, PhD
Affiliation: David Tvildiani Medical University (DTMU)
First published: January 2026
Last reviewed: 2026-05-29
Next review: February 2027
References: 2 cited sources
COI: SupplementIndex receives no funding from supplement manufacturers. All content independently authored by PHIG.
Process: Systematic literature review
📄 License & reuse
Published under Creative Commons Attribution 4.0 International (CC BY 4.0). You may share and adapt for any purpose with attribution.
Pkhakadze G. "Omega-3 EPA — Safety Profile." SupplementIndex, PHIG, 2026. https://supplement.ge/ingredients/epa/ CC BY 4.0.
GP
Prof. G. Pkhakadze, MD, MPH, PhD
Professor of Public Health · Head of Department, DTMU
Editor-in-Chief, Georgian Medical Journal (ISSN 3088-4322)
Chair, Public Health Institute of Georgia · UEMS Public Health Section
Educational and public health purposes. CC BY 4.0. Consult your healthcare provider before starting any supplement. Corrections: info@accreditation.ge. Publisher: PHIG